Tenax Therapeutics Q1 net loss widens on higher R&D costs

Tenax Therapeutics

12/05/2026 12:08

Overview

US cardiopulmonary drug developer's Q1 net loss widened yr/yr due to higher R&D costs

Company expects cash and equivalents to fund operations through at least Q1 2028

Leadership team expanded with new CFO, CCO, and EVP of Clinical Development

Outlook

Tenax expects to report topline data from the LEVEL study in Q3 2026

Company anticipates completing enrollment for LEVEL-2 trial by end of 2027

Tenax expects cash and cash equivalents to fund operations through at least Q1 2028

Result Drivers

R&D SPENDING - Higher clinical and preclinical development costs for Phase 3 LEVEL and LEVEL-2 trials drove increased R&D expenses

OPERATIONAL MILESTONES - Completion of patient randomization in LEVEL study and ongoing site activations for LEVEL-2 trial

Company press release: ID:nGNX7lxFwW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$15.72 mln
Q1 Operating Expenses
$16.57 mln
Q1 Operating Income
-$16.57 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Tenax Therapeutics Inc is $30.00, about 151% above its May 11 closing price of $11.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)